上海复星医药（集团）股份有限公司 关于 2025 年 A 股股票期权激励计划内幕信息知情人 买卖本公司股票情况的自查报告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 2025 年 8 月 22 日，上海复星医药（集团）股份有限公司（以下简称"本公 司"）第十届董事会第七次会议审议通过《上海复星医药（集团）股份有限公司 2025 年 A 股股票期权激励计划（草案）》（以下简称"本次激励计划"）及其摘要 等相关议案，相关公告于 2025 年 8 月 23 日刊载于上海证券交易所网站 （http://www.sse.com.cn）以及《中国证券报》《上海证券报》《证券时报》。 根据中国证券监督管理委员会《上市公司股权激励管理办法》（以下简称"《管 理办法》"）的要求，本公司对本次激励计划的内幕信息知情人进行了登记，并对 本次激励计划内幕信息知情人于本次激励计划公开披露前六个月内（即 2025 年 2 月 23 日至 2025 年 8 月 22 日，以下简称"本次自查期间"）买卖本公司 A 股股 票的情况进行了自查，具体情况如下： 一、核查的范围与程序 1、核查对 ...

国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 关于上海复星医药（集团）股份有限公司 2025 年第一次临时股东会 的法律意见书 致：上海复星医药（集团）股份有限公司 国浩律师（上海）事务所（以下简称"本所"），接受上海复星医药（集团） 股份有限公司（以下简称"公司"）的委托，指派本所律师出席公司 2025 年第一 次临时股东会（以下简称"本次股东会"），并根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）以及《上海复星医药（集 团）股份有限公司章程》（以下简称"《公司章程》"）的规定出具本法律意见书。 本所依据本法律意见书出具日之前已经发生或存在的事实及中国（为出具本 法律意见书之目的，本法律意见书中的"中国"仅指中国大陆地区，不包括香港 特别行政区和澳门特别行政区及台湾地区）现行法律、法规及规范性文件发表法 律意见。 本所同意将本法律意见书作为公司本次股东会公告的法定文件，随公司其他 公告一并提交上海证券交易所审查并予公告。 在本法律意见书中，本所律师仅对本次股东会的召集和召开程序 ...

证券代码：600196 证券简称：复星医药 公告编号：2025-162 上海复星医药（集团）股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议有无否决议案：无 一、 会议召开和出席情况 （一）股东会召开的时间：2025 年 10 月 23 日 （二）股东会召开的地点：上海市虹许路 358 号上海天禧嘉福璞缇客酒店 （三）出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 1,640 | | --- | --- | | 其中：境内上市内资股（A 股）股东人数 | 1,639 | | 境外上市外资股（H 股）股东人数 | 1 | | 2、出席会议的股东所持有表决权的股份总数（股） | 1,100,625,377 | | 其中：境内上市内资股（A 股）股东持有表决权股份总数（股） | 977,104,664 | | 境外上市外资股（H 股）股东持有表决权股份总数（股） | 123,520,713 | | 注的 ...

Core Viewpoint - The Medical Health Index (980016) closed at 6646.6 points, down 0.3%, with a trading volume of 19.922 billion yuan and a turnover rate of 0.75% on October 23 [1] Group 1: Index Performance - Among the constituent stocks of the Medical Health Index, 16 stocks rose while 31 stocks fell, with Kanglong Chemical leading the gainers at 1.55% and Te Bao Biological leading the decliners at 6.07% [1] - The top ten constituent stocks of the Medical Health Index include: - WuXi AppTec (14.37% weight, latest price 101.90, market cap 304.045 billion yuan) - Hengrui Medicine (11.45% weight, latest price 65.14, market cap 432.347 billion yuan) - Mindray Medical (8.07% weight, latest price 221.80, market cap 268.920 billion yuan) [1] Group 2: Capital Flow - The net outflow of main funds from the constituent stocks of the Medical Health Index totaled 1.072 billion yuan, while retail investors saw a net inflow of 955 million yuan [3] - Detailed capital flow for key stocks includes: - Mindray Medical: Main net inflow of 66.9479 million yuan, retail net inflow of 3.6088 million yuan - Te Bao Biological: Main net inflow of 29.0966 million yuan, retail net outflow of 41.3737 million yuan [3]

Core Viewpoint - Southbound funds increased their holdings in Fosun Pharma (02196.HK) by 316,500 shares on October 22, 2025, despite experiencing net reductions in holdings on several days in the preceding weeks [1][2]. Group 1: Shareholding Changes - Over the last five trading days, there were two days of net reductions in holdings, totaling a net decrease of 296,000 shares [1]. - In the last twenty trading days, there were twelve days of net reductions, resulting in a cumulative net decrease of 16.5155 million shares [1]. - As of now, southbound funds hold 306 million shares of Fosun Pharma, accounting for 55.51% of the company's total issued ordinary shares [1]. Group 2: Company Overview - Fosun Pharma is primarily engaged in the research, manufacturing, and sales of pharmaceutical products, operating through five divisions [2]. - The pharmaceutical division focuses on innovative drugs, mature pharmaceutical products, and vaccines [2]. - The medical devices and diagnostics division is involved in the manufacturing and sales of molecular diagnostics, immunodiagnostics, and microbiological diagnostic devices [2]. - The healthcare services division operates an integrated online and offline medical service platform [2]. - The pharmaceutical distribution and retail division is responsible for the wholesale and retail of pharmaceutical products [2]. - The company's products are mainly used in the treatment of oncology, immunology, and central nervous system disorders [2].

10月22日，据复星医药消息，近日，复星医药与赫尔森集团共同宣布，双方达成了止吐药物磷奈匹坦帕 洛诺司琼注射用浓溶液本地化生产战略合作。 ...

Economic Overview - Shanghai's GDP for the first three quarters reached 40,721.17 billion yuan, with a year-on-year growth of 5.5% [1] - The industrial production maintained a growth trend, with the industrial added value increasing by 5.2% year-on-year [2] Industrial Performance - The total industrial output value for large-scale industries in Shanghai grew by 5.7% year-on-year, with an acceleration of 0.1 percentage points compared to the first half of the year [2] - Key sectors such as railway, shipbuilding, aerospace, and other transportation equipment manufacturing saw a significant increase of 15.9% [2] - Electrical machinery and equipment manufacturing grew by 14.3%, while computer, communication, and other electronic equipment manufacturing increased by 12.1% [2] Investment Trends - Industrial investment in Shanghai rose by 20.3%, outpacing the overall fixed asset investment growth rate of 14.3 percentage points [2] - The resilience and internal driving force of industrial growth have been enhanced, indicating a positive investment outlook for future production [2] Emerging Industries - The three leading industries in Shanghai experienced an 8.5% increase in output value, surpassing the overall industrial growth by 2.8 percentage points [3] - The artificial intelligence manufacturing sector grew by 12.8%, and integrated circuit manufacturing increased by 11.3% [3] - High-tech manufacturing output value rose by 10.3%, with aerospace and communication equipment manufacturing growing by 20.6% and 13.4%, respectively [3] Strategic Initiatives - Shanghai is focusing on enhancing its artificial intelligence industry by aiming for a tripling of innovative enterprises, industry scale, and talent [4] - The city has established 12 national-level intelligent factories and 254 advanced intelligent factories, leading the nation in smart manufacturing [4] - In the biopharmaceutical sector, Shanghai's industry scale is expected to exceed 1 trillion yuan this year, with significant advancements in innovative drug approvals [5] Future Industry Development - Shanghai aims to cultivate a number of future industry clusters and lead in disruptive technologies by 2027 [5] - The city plans to nurture around 20 leading enterprises in future industries and establish itself as a globally influential hub by 2030 [5]

Meeting Overview - The company will hold its first extraordinary general meeting of 2025 on October 23, 2025, at 13:30 in Shanghai [1][4] - The meeting will be conducted using a combination of on-site and online voting methods [4][10] Voting Procedures - A-share shareholders can vote through the Shanghai Stock Exchange's online voting system, with specific time slots for voting on the meeting day [1][7] - Shareholders must complete identity verification to vote on the internet for the first time [7] - Votes exceeding the number of shares held will be considered invalid [8] Attendance and Registration - A-share shareholders must register in person with required identification and documentation on the day of the meeting [15] - H-share shareholders have separate registration procedures detailed on the Hong Kong Stock Exchange website [11][16] Agenda Items - The meeting will review several resolutions, including special resolutions and those requiring abstention from related shareholders [3][5] - Detailed agenda items were published on September 30, 2025 [3][4]

Core Insights - The attitude of foreign capital towards Chinese medical assets has dramatically reversed within a year, shifting from a neutral to a positive outlook on the biotechnology sector in China [1][3][7] Group 1: Market Sentiment Shift - Morgan Stanley's report titled "China Biotech: Innovation Dawn" indicates that China's biotechnology sector is now viewed as a critical part of the global new drug supply chain, with projected pharmaceutical revenues reaching $34 billion by 2030 and $220 billion by 2040 [1][3] - The number of foreign institutions conducting research on Chinese biotech companies has surged, with notable firms like State Street Bank and BlackRock showing increased interest [1][2] - The collective buying actions of foreign investors, such as JPMorgan and Citigroup, reflect a significant shift in sentiment towards Chinese innovative drug companies [2][5] Group 2: Investment Dynamics - The efficiency of converting research interest into actual holdings is evident, as seen in the stock price surge of WuXi AppTec, which rose by 6.52% due to increased foreign investment [2] - Major foreign investors have increased their holdings in key Chinese biotech firms, indicating a trend of strategic accumulation among top foreign capital [5][6] - The report highlights that foreign capital is now viewing specific sectors in China as essential assets in the global technology race, with over 90% of U.S. investors expressing plans to increase exposure to Chinese stocks, particularly in biotechnology [6][7] Group 3: Industry Evolution - The narrative surrounding China's pharmaceutical industry has shifted from being cost-driven to innovation-driven, acknowledging the significant advancements in the sector [3][4] - Morgan Stanley and Goldman Sachs both emphasize the growing recognition of China's innovative capabilities in biotechnology, with expectations that several leading biotech firms will reach breakeven by 2025-2026 [4][8] - The report outlines that the Chinese biotech sector is becoming a key player in filling the revenue gaps created by patent expirations in multinational corporations (MNCs), with an estimated $115 billion revenue loss due to patent cliffs by 2035 [8][10] Group 4: Future Projections - By 2040, China's share of FDA-approved drugs is expected to rise from 5% to 35%, with a projected global sales figure exceeding $1.22 trillion even in the most pessimistic scenarios [25][27] - The report anticipates that the collaboration between MNCs and Chinese biotech firms will intensify, driven by the need to address revenue shortfalls from patent expirations [10][14] - The overall improvement in clinical trial data integrity and the increasing number of new molecular entities launched in China are contributing to a more favorable investment landscape [20][22]

Meeting Overview - The company will hold its first extraordinary general meeting of 2025 on October 23, 2025, at 13:30 in Shanghai [1][4] - The meeting will utilize both on-site and online voting methods [4] Voting Procedures - Online voting will be available from 9:15 to 15:00 on the day of the meeting, with specific time slots for trading system voting [1][4] - A-share shareholders can vote through the Shanghai Stock Exchange's online voting system [6][9] Agenda Items - The meeting will discuss several special resolution proposals, including items 1 to 5, and separate voting for minority investors on items 1 to 8 [5][6] - Related proposals will require certain shareholders to abstain from voting [6] Attendance Requirements - A-share shareholders must register for the meeting with appropriate identification and documentation [11][12] - H-share shareholders have specific registration procedures detailed on the Hong Kong Stock Exchange website [10][13] Additional Information - Shareholders are responsible for their own travel and accommodation expenses [14] - Contact information for the company's board secretary office is provided for further inquiries [15]